Cardio Diagnostics Holdings, Inc. (CDIO)
US — Healthcare Sector
Automate Your Wheel Strategy on CDIO
With Tiblio's Option Bot, you can configure your own wheel strategy including CDIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CDIO
- Rev/Share 0.0118
- Book/Share 6.7474
- PB 0.5913
- Debt/Equity 0.0532
- CurrentRatio 19.4879
- ROIC -0.4873
- MktCap 6937453.0
- FreeCF/Share -3.1977
- PFCF -1.2867
- PE -1.1491
- Debt/Assets 0.0493
- DivYield 0
- ROE -0.8456
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split
CDIO
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings today announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13, 2025.
Read More
Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session
CDIO
Published: March 26, 2025 by: Business Wire
Sentiment: Neutral
Published: March 26, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its growing portfolio of advanced cardiovascular solutions at the ACC's 74th Annual Scientific Session & Expo.
Read More
About Cardio Diagnostics Holdings, Inc. (CDIO)
- IPO Date 2022-01-14
- Website https://cardiodiagnosticsinc.com
- Industry Biotechnology
- CEO Dr. Meeshanthini V. Dogan Ph.D.
- Employees 13
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.